Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal
November 27, 2021 at 14:30 PM EST
In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to acquire Zenas shares up to 15% of Zenas’ equity.
